Healthcare Aug 31, 2021 05:29 PM (GMT+8) · EqualOcean
On August 31, Dashi pharmaceutical announced that it had recently completed a round of financing of nearly 100 million yuan. This round of financing was led by Kaitai capital, and pre-A round of investors Shenzhen sharing investment and Zhongshan Xiangshang investment continued to participate in this round of financing. The funds obtained in this round of financing will be mainly used to promote the phase 1 and phase 2A clinical research and development of the company's first non addictive long-acting analgesic ds002. In addition, it will also be used to enrich the company's R & D pipeline, build CMC pilot platform, expand talent team and other company operation needs.